Chimerix commences first-in-human research of CMX157 for HIV Chimerix.

CMX157 gets the potential to increase efficacy and lower toxicity as compared to tenofovir, and may enable the creation of brand-new 'one pill, once-a-day', fixed-dose mixture regimens for the treating HIV infection. The Stage 1 dose-escalating clinical research is designed to evaluate the security, tolerability and pharmacokinetics of CMX157. In addition to monitoring protection and regular PK parameters in plasma, degrees of the active antiviral will be established in peripheral blood mononuclear cells . These data provides insight into the potential efficacy of CMX157, as the degrees of tenofovir diphosphate in PBMCs linked to the antiviral efficacy of Viread have been documented. Related StoriesGenvoya authorized as complete routine for HIV treatmentResearch provides qualified prospects for new ways of develop HIV vaccineRutgers College of Nursing takes lead in $6 million nationwide effort to avoid new HIV infections We are pleased to advance CMX157 into human clinical research.James Stein of the University of Wisconsin-Madison. He is a leading researcher on imaging artery buildups and before consulted for Schering-Plough Corp., that used to market Vytorin with Merck. Dr. Sidney Smith, a former center association president from the University of NEW YORK at Chapel Hill, said that for those who have newly diagnosed cholesterol problems, ‘the foundation continues to be statins.’ The new study ‘affirms the benefits of niacin’ and helps it be the next drug to add if people need more help, he said. Dr. Anthony DeMaria, a former president of the American College of Cardiology from the University of California at NORTH PARK, said the study ‘doesn’t quite place the nail in the coffin’ for Zetia, but pushes it way down on the list of things to try. Last year, a big study discovered that the combo tablet Vytorin was no more effective than Zocor by itself, a statin obtainable as an inexpensive generic now.